The Competition Commission of India is not ready to approve of the proposed acquisition of Ranbaxy by Sun Pharmaceutical, say reports.
The watchdog said Thursday that it has made initial observations about the $3.2 billion takeover that suggest the deal may hurt competition. The CCI how now asked the companies to provide more information on the deal.
The companies now have 10 working days to submit the information.
The companies first agreed on a merger deal last April; Ranbaxy is currently owned by Japan-based Daiichi Sankyo. Should all the necessary regulators approve of the deal, the newly combined company would be the world’s fifth-largest generic drug maker, reports say.
Full content: Business Standard
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Chilean Lithium Deal Advances, Eyes Finalization This Year
Apr 24, 2025 by
CPI
South Dakota Reaches Settlement With NCAA Ahead of Antitrust Payout Approval
Apr 23, 2025 by
CPI
Judge Allows Yelp’s Antitrust Lawsuit Against Google to Proceed
Apr 23, 2025 by
CPI
Meta Lawyers Try to Undercut Instagram Co-Founder’s Damaging Testimony
Apr 23, 2025 by
CPI
Tyson Foods, Others Settle Pork Price-Fixing Suit for $64 Million
Apr 23, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece